Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety ...

Shares of Sarepta Therapeutics, Inc. (SRPT) traded over 2% lower in afternoon trade on Friday after the company said it has ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...

Sarepta and Roche announced a 16-year-old US patient dosed with Elevidys died of acute liver failure in March 2025.

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Therapeutics shared the following update related to ELEVIDYS, the only approved gene therapy in patients with Duchenne muscular ...

Sarepta Therapeutics ... shared the following update related to ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

The firm said the clinical trial pause is temporary as an independent data monitoring committee finalizes its analysis for submission to regulators.

The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal ...

The determination comes after recruitment and dosing in certain trials were paused after a young patient died due to acute ...

April 4 (Reuters) - Sarepta Therapeutics (SRPT.O), opens new tab said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last ...